Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species

Chemico-Biological Interactions

Volumn 106, Issue 3, 1997, Pages 161-182

  Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P450; Genetic polymorphisms; Site directed mutagenesis; Species comparisons

Indexed keywords

CYTOCHROME P450;

AMINO ACID SEQUENCE; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; NONHUMAN; SHORT SURVEY; SITE DIRECTED MUTAGENESIS; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0030735150     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00068-9     Document Type: Review

References (170)

1. G. Palmer, J. Reedijk, Nomenclature of electron-transfer proteins. Recommendations 1989, J. Biol. Chem. 267 (1992) 665-677.
2. Y. Higashi, T. Hiromasa, A. Tanae, T. Miki, J. Nakura, T. Kondo, T. Ohura, E. Ogawa, K. Nakayama, Y. Fujii-Kuriyama, Effects of individual mutations in the P-450 (C21) pseudogene on the P-450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency, J. Biochem. 109 (1991) 638-644.
3. D.S. Keeney, M.R. Waterman, Regulation of steroid hydroxylase gene expression: importance to physiology and disease, Pharmacol. Ther. 58 (1993) 301-317.
4. H.F. DeLuca, The vitamin D story: a collaborative effort of basic science and clinical medicine, FASEB J. 2 (1988) 224-236.
5. J.H. Capdevila, D. Zeldin, K. Makita, A. Karara, J.R. Falck. Cytochrome P450 and the metabolism of arachidonic acid and oxygenated eicosanoids, in: P.R. Ortiz de Montellano (Ed.), Cytochrome P450: Structure, Mechanism and Biochemistry, Plenum, New York, 1995, pp. 443-471.
6. H. Kodaira, S. Spector, Transformation of thebaine to oripavine, codeine, and morphine by rat liver, kidney and brain microsomes, Proc. Natl. Acad. Sci. USA 85 (1988) 1267-1271.
7. W.B. Jakoby, Detoxication enzymes, in: W.B. Jakoby (Ed.), Enzymatic Basis of Detoxication, Vol. 1, Academic Press, New York, 1980, pp. 1-6.
8. F.P. Guengerich, Cytochrome P450 enzymes, Am. Sci. 81 (1993) 440-447.
9. F.P. Guengerich, Human cytochrome P450 enzymes, in: P.R. Ortiz de Montellano (Ed.), Cytochrome P450, Plenum, New York, 1995, pp. 473-535.
10. F.J. Gonzalez, D.W. Nebert, Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation, Trends Genet. 66 (1990) 164-168.
11. D.R. Nelson, T. Kamataki, D.J. Waxman, F.P. Guengerich, R.W. Estabrook, R. Feyereisen, F.J. Gonzalez, M.J. Coon, I.C. Gunsalus, O. Gotoh, K. Okuda, D.W. Nebert, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature, DNA Cell Biol. 12 (1993) 1-51.
12. F.P. Guengerich, G.A. Dannan, S.T. Wright, M.V. Martin, L.S. Kaminsky, Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone, Biochemistry 21 (1982) 6019-6030.
13. D.E. Ryan, P.E. Thomas, D. Korzeniowski, W. Levin, Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphenyls, phenobarbital, and 3-methylcholanthrene, J. Biol. Chem. 254 (1979) 1365-1374.
14. D. Ryan, A.Y.H. Lu, J. Kawalek, S.B. West, W. Levin, Highly purified cytochrome P-448 and P-450 from rat liver microsomes, Biochem. Biophys. Res. Commun. 64 (1975) 1134-1141.
15. L.M. Distlerath, P.E.B. Reilly, M.V. Martin, G.G. Davis, G.R. Wilkinson, F.P. Guengerich, Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylaticn, two prototypes for genetic polymorphism in oxidative drug metabolism, J. Biol. Chem. 260 (1985) 9057-9067.
16. D.W. Nebert, M. Adesnik, M.J. Coon, R.W. Estabrook, F.J. Gonzalez, F.P. Guengerich, I.C. Gunsalus, E.F. Johnson, B. Kemper, W. Levin, I.R. Phillips, R. Sato, M.R. Waterman, The P450 gene superfamily: recommended nomenclature, DNA 6 (1987) 1-11.
17. D.W. Nebert, D.R. Nelson, M. Adesnik, M.J. Coon, R.W. Estabrook, F.J. Gonzalez, F.P. Guengerich, I.C. Gunsalus, E.F. Johnson, B. Kemper, W. Levin, I. Phillips, R. Sato, M. Waterman, The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci, DNA 8 (1989) 1-13.
18. D.W. Nebert, D.R. Nelson, M.J. Coon, R.W. Estabrook, R. Feyereisen, Y. Fujii-Kuriyama, F.J. Gonzalez, F.P. Guengerich, I.C. Gunsalus, E.F. Johnson, J.C. Loper, R. Sato, M.R. Waterman, D.J. Waxman, The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature, DNA Cell Biol. 10 (1991) 1-14.
19. D.W. Nebert, D.R. Nelson, M.J. Coon, R.W. Estabrook, R. Feyereisen, Y. Fujii-Kuriyama, F.J. Gonzalez, F.P. Guengerich, I.C. Gunsalus, E.F. Johnson, J.C. Loper, R. Sato, M.R. Waterman, D.J. Waxman, The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature, DNA Cell Biol. 10 (1991) 397-398.
20. D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus, D.W. Nebert, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics 6 (1996) 1-42.
21. R. Naït-Kaoudjt, R. Williams, B. Guiard, M. Gervais, Some DNA targets of the yeast CYP1 transcriptional activator are functionly asymmetric: evidence of two half-sites with different affinities, Eur. J. Biochem. 244 (1997) 301-309.
22. A.K. Jaiswal, F.J. Gonzalez, D.W. Nebert, Human dioxin-inducible cytochrome P1-450: complementary DNA and amino acid sequence, Science 228 (1985) 80-83.
23. F.P. Guengerich, Separation and purification of multiple forms of microsomal cytochrome P-450. Partial characterization of three apparently homogeneous cytochromes P-450 prepared from livers of phenobarbital- and 3-methylcholanthrene-treated rats, J. Biol. Chem. 253 (1978) 7931-7939.
24. D.R. Koop, M.J. Coon, Purification of liver microsomal cytochrome P-450 isozymes 3a and 6 from imidazole-treated rabbits, Mol. Pharmacol. 25 (1984) 494-501.
25. E.F. Johnson, U. Muller-Eberhard, Resolution of two forms of cytochrome P-450 from liver microsomes of rabbits treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin, J. Biol. Chem. 252 (1977) 2839-2845.
26. M. Negishi, D.W. Nebert, Structural gene products of the Ah locus: genetic and immunochemical evidence for two forms of mouse liver cytochrome P-450 induced by 3-methylcholanthrene, J. Biol. Chem. 254 (1979) 11015-11023.
27. T. Shimada, C.H. Yun, H. Yamazaki, J.C. Gautier, P.H. Beaune, F.P. Guengerich, Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens, Mol. Pharmacol. 41 (1992) 856-864.
28. N. Battula, J. Sagara, H.V. Gelboin, Expression of P3-450 and P3-450 DNA coding sequences as enzymatically active cytochromes P-450 in mammalian cells, Proc. Natl. Acad. Sci. USA 84 (1987) 4073-4077.
29. S. Dogra, J. Doehmer, H. Glatt, H. Mölders, P. Siegert, T. Friedberg, A. Seidel, F. Oesch, Stable expression of rat cytochrome P-450IA1 cDNA in V79 Chinese hamster cells and their use in mutagenicity testing, Mol. Pharmacol. 37 (1990) 608-613.
30. H.P. Eugster, C. Sengstag, U.A. Meyer, A. Hinnen, F.E. Würgler, Constitutive and inducible expression of human cytochrome P450IA1 in yeast Saccharomyces cerevisiae: an alternative enzyme source for in vitro studies, Biochem. Biophys. Res. Commun. 172 (1990) 737-744.
31. Z. Guo, E.M.J. Gillam, S. Ohmori, R.H. Tukey, F.P. Guengerich, Expression of modified human cytochrome P450 1A1 in Escherichia coli: effects of 5′ substitution, stabilization, purification, spectral characterization and catalytic properties, Arch. Biochem. Biophys. 312 (1994) 436-446.
32. Y.-J. Chun, T. Shimada, F.P. Guengerich, Construction of a human cytochrome P450 1A1:rat NADPH-F450 1A1 in Escherichia coli: effects of 5′ substitution, stabilization, purification, spectral characterization and catalytic properties, Arch. Biochem. Biophys. 312 (1994) 737-744.
33. A. Parikh, E.M.J. Gillam, F.P. Guengerich, Drug metabolism by Escherichia coli expressing human cytochromes P450, Nature Biotechnol. 15 (1997) 784-788.
34. A.H. Conney, Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes memorial lecture, Cancer Res. 42 (1982) 4875-4917.
35. M.D. Burke, R.T. Mayer, Inherent specificities of purified cytochromes P-450 and P-448 toward biphenyl hydroxylation and ethoxyresorufin deethylation, Drug Metab. Dispos. 3 (1975) 245-253.
36. M.D. Burke, S. Thompson, C.R. Elcombe, J. Halpert, T. Haarparanta, R.T. Mayer, Ethoxy-, pentoxy-and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450, Biochem. Pharmacol. 34 (1985) 3337-3345.
37. E. Bauer, Z. Guo, Y.-F. Ueng, L.C. Bell, F.P. Guengerich, Oxidation of benzo(a)pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8 (1995) 136-142.
38. L.S. Kaminsky, G. A. Dannan, F.P. Guengerich, Composition of cytochrome P-450 isozymes from hepatic microsomes of C57BL/6 and DBA/2 mice assessed by warfarin metabolism, immunoinhibition and immunoelectrophoresis with anti-(rat cytochrome P-450), Eur. J. Biochem. 141 (1984) 141-148.
39. D.E. Ryan, P.E. Thomas, W. Levin, Hepatic microsomal cytochrome P-450 from rats treated with isosafrole: purification and characterization of four enzymic forms, J. Biol. Chem. 255 (1980) 7941-7955.
40. G.J. Fisher, H. Fukushima, J.L. Gaylor, Isolation, purification and properties of a unique form of cytochrome P-450 in microsomes of isosafrole-treated rats, J. Biol. Chem. 255 (1981) 4388-4394.
41. J.A. Goldstein, P. Linko, M.I. Luster, D.W. Sundheimer, Purification and characterization of a second form of hepatic cytochrome P-448 from rats treated with pure polychlorinated biphenyl isomer, J. Biol. Chem. 257 (1982) 2702-2707.
42. D.A. Haugen, T.A. van der Hoeven, M.J. Coon, Purified liver microsomal cytochrome P-450: separation and characterization of multiple forms, J. Biol. Chem. 250 (1975) 3567-3570.
43. C. Hashimoto, Y. Imai, Purification of a substrate complex of cytochrome P-450 from liver microsomes of 3-methylcolanthrene-treated rabbits, Biochem. Biophys. Res. Commun. 68 (1976) 821-827.
44. 3-450: cDNA and complete protein sequence, repetitive Alu sequences in the 3′ nontranslated region and localization of gene to chromosomes 15, J. Exp., Pathol. 3 (1987) 117.
45. P. Sandhu, Z. Guo, T. Baba, M.V. Martin, R.H. Tukey, F.P. Guengerich, Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization and catalytic activities of the enzyme, Arch. Biochem. Biophys. 309 (1994) 168-177.
46. K. Ishii, Y. Yamazoe, T. Kamataki, R. Kato, Metabolic activation of glutamic acid pyrolysis products, 2-amino-6-methyldipyrido[1,2-a:3′,2′-d]imidazole and 2-amino-dipyrido[1,2-a:3′,2′-d]imidazole, by purified cytochrome P-450, Chem.-Biol. Interact. 38 (1981) 1-13.
47. T. Shimada, M. Iwasaki, M.V. Martin, F.P. Guengerich, Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procrcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002, Cancer Res 49 (1989) 3218-3228.
48. Y. Yamazoe, M. Shimada, K. Maeda, T. Kamataki, R. Kato, Specificity of four forms of cytochrome P-450 in the metabolic activation of several aromatic amines and benzo[a]pyrene, Xenobiotica 14 (1984) 549-552.
49. d wild type, proximal mutants and distal mutants, Biochemistry 30 (1991) 1490-1496.
50. d by site-directed mutagenesis, J. Biol. Chem. 266 (1991) 3372-3375.
51. d changed regio-specificity of acetanilide hydroxylations, Biochem. Biophys. Res. Commun. 160 (1989) 669-676.
52. ds: effects of mutations at putative distal sites in the presence of polycyclic hydrocarbons, Biochemistry 30 (1991) 4659-4662.
53. d (P4501A2): effects of mutations on the methanol hydroxylation, FASEB J. 6 (1992) 749-751.
54. d-phenyl isocyanide complexes: effects of mutations at the putative distal site on the conformational stability. Biochemistry 30 (1991) 11206-11211.
55. d, Biochemistry 31 (1992) 1528-1531.
56. d: catalytic activities toward benzphetamine and 7-ethoxycoumarin, Biochemistry 28 (1989) 6848-6857.
57. PA (P-450IA2), the phenacetin O-deethylase is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines, Proc. Natl. Acad. Sci. USA 86 (1989) 7696-7700.
58. C.D. Davis, R.H. Adamson, E.G. Snyderwine, Studies on the mutagenic activation of heterocylic amines by cynomolgous monkey, rat and human microsomes show that cynomolgus monkeys have a low capacity to N-oxidize the quinoxaline-type heterocyclic amines, Cancer Lett. 73 (1993) 95-104.
59. P. Honkakosi, M. Negishi, The structure, function and regulation of cytochrome P450 2A enzymes, Drug Metab. Rev. (1997) (in press).
60. coh substrate specificity by mutation of a single amino-acid residue, Nature 339 (1989) 632-634.
61. coh to a novel corticosterone 15α-hydroxylase and modeling steroid-binding orientation in the substrate pocket, J. Biol. Chem. 268 (1993) 759-762.
62. M. Iwasaki, T.A. Darden, L.G. Pedersen, M. Negishi, Altering the regiospecificity of androstenedione hydroxylase activity in P450s 2a-4/5 by a mutation of the residue at position 481, Biochemistry 34 (1995) 5054-5059.
63. M. Iwasaki, D.G. Davis, T.A. Darden, L.G. Pedersen, M. Negishi, Multiple steroid binding orientations: alteration of regiospecificity of dehydroepiandrosterone 2- and 7-hydroxylase activities of cytochrome P-450 2a-5 by mutation of residue 209, Biochem. J. 306 (1995) 29-33.
64. 1 with cytochrome P450 2A5 and its mutants: correlation with metabolic activation and toxicity, Chem. Res. Toxicol. 10 (1997) 85-90.
65. T. Shimada, H. Yamazaki, M. Mimura, Y. Iriui, F.P. Guengerich, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther. 270 (1994) 414-423.
66. S. Yamano, J. Tatsuno, F.J. Gonzalez, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes, Biochemistry 29 (1990) 1322-1329.
67. C. Liu, X. Zhuo, F.J. Gonzalez, X. Ding, Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants, Mol. Pharmacol. 50 (1996) 781-788.
68. G.P. Valusk, J. Ghrayeb, D.E. Ryan, L. Reik, P.E. Thomas, W. Levin, F.G. Walz Jr., Multiplicity, strain differences and topology of phenobarbital-induced cytochromes P-450 in rat liver microsomes, Biochemistry 21 (1982) 789-798.
69. P.M. Yuan, D.E. Ryan, W. Levin, J.E. Shively, Identification and localization of amino acid substitutions between two phenobarbital-inducible rat hepatic microsomal cytochromes P-450 by microssequence analyses, Proc. Natl. Acad. Sci. USA 80 (1983) 1169-1173.
70. D.E. Ryan, P.E. Thomas, L.M. Reik, W. Levin, Purification, characterization and regulation of five rat hepatic microsomal cytochrome P-450 isozymes, Xenobiotica 12 (1982) 727-744.
71. K.M. Kedzie, C.A. Balfour, G.Y. Escobar, S.W. Grimm, Y. He, D.J. Pepperl, J.W. Regan, J.C. Stevens, J.R. Halpert, Molecular basis for a functionally unique cytochrome P450IIB1 variant, J. Biol. Chem. 266 (1991) 22515-22521.
72. Y. He, C.A. Balfour, K.M. Kedzie, J.R. Halpert, Role of residue 478 as a determinant of the substrate specificity of cytochrome P450 2B1, Biochemistry 31 (1992) 4453-4457.
73. J.R. Halpert, Y. He, Engineering of cytochrome P450 2B1 specificity: conversion of an androgen 16β-hydroxylase, J. Biol. Chem. 268 (1993) 4453-4457.
74. T. Aoyama, K. Korzekwa, K. Nagata, M. Adesnik, A. Reiss, D.P. Lapenson, J. Gilette, H.V. Gelboin, D.J. Waxman, F.J. Gonzalez. Sequence requirements for cytochrome P-450IIB1 catalytic activity: alteration of the stereospecificity and regioselectivity of steroid hydroxylation by a simultaneous change of two hydrophobic amino acid residues to phenylalanine, J. Biol. Chem. 264 (1989) 21327-21333.
75. Z. Luo, Y. He, J.R. Halpert, Role of residues 363 and 206 in conversion of cytochrome P450 2B1 from a steroid 16-hydroxylase to a 15α-hydroxylase, Arch. Biochem. Biophys. 309 (1994) 52-57.
76. Y.Q. He, Y. A. He, J.R. Halpert, Escherichia coli expression of site-directed mutants of cytochrome P450 2B1 from six substrate recognition sites: substrate specificity and inhibitor selectivity studies, Chem. Res. Toxicol. 8 (1995) 574-579.
77. T.A. van der Hoeven, D.A. Haugen. M.J. Coon, Cytochrome P-450 purified to apparent homogeneity from phenobarbital-induced rabbit liver microsomes: catalytic activity and other properties, Biochem. Biophys. Res. Commun. 60 (1974) 569-575.
78. Y. Imai, R. Sato, A gel-electrophoretically homogeneous preparation of cytochrome P-450 from liver microsomes of phenobarbital-pretreated rabbits, Biochem. Biophys. Res. Commun. 60 (1974) 8-14.
79. S.W. Grimm, M.C. Dyroff, R.M. Philpot, J.R. Halpert, Catalytic selectivity and mechanism-based inactivation of stably expressed and hepatic cytochromes P450 2B4 and 2B5: implications of the cytochrome P450 2B5 polymorphism, Mol. Pharmacol. 46 (1994) 1090-1099.
80. Y. Imai, M. Komori, R. Sato, Comparison of primary structures deduced from cDNA nucleotide sequences for various forms of liver microsomal cytochrome P-450 from phenobarbital-treated rabbits, Biochemistry 27 (1988) 80-88.
81. G.D. Szklarz, Y.Q. He, K.M. Kedzie, J.R. Halpert, V.L. Burnett, Elucidation of amino acid residues critical for unique activities of rabbit cytochrome P450 2B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome P450 2B4, Arch. Biochem. Biophys. 327 (1996) 308-318.
82. K.M. Kedzie, S.W. Grimm, F. Chen, J.R. Halpert, Hybrid enzymes for structure-function analysis of cytochrome P-450 2B11, Biochim. Biophys. Acta 1154 (1993) 124-132.
83. J. Liu, Y. A. He, J.R. Halpert, Role of residue 480 in substrate specificity of cytochrome P450 2B5 and 2B11, Arch. Biochem. Biophys. 327 (1996) 167-173.
84. J.A. Hasler, G.R. Harlow, G.D. Szlarz, G.H. John, K.M. Kedzie, V.L. Burnett, Y.A. He, L.S. Kaminsky, J.R. Halpert, Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290 and 363 for substrate specificity, Mol. Pharmacol. 46 (1994) 338-345.
85. S. Yamano, P.T. Nhamburo, T. Aoyama, U.A. Meyer, T. Inaba, W. Kalow, H.V. Gelboin, O.W. McBride, F.J. Gonzalez, cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: in identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver, Biochemistry 28 (1989) 7340-7348.
86. M. Mimura, T. Baba, Y. Yamazaki, S. Ohmori, Y. Inui, F.J. Gonzalez, F.P. Guengerich, T. Shimada, Characterization of cytochrome P450 2B6 in human liver microsomes, Drug Metab. Dispos. 21 (1993) 1048-1056.
87. T.K.H. Chang, G.F. Weber, C.L. Crespi, D.J. Waxman, Differential activation of cyclophos-phamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53 (1993) 5629-5637.
88. A.M. Flammang, H.V. Gelboin, T. Aoyama, F.J. Gonzalez, G.D. McCoy, Nicotine metabolism by cDNA-expressed human cytochrome P-450s, Biochem. Arch. 8 (1992) 1-8.
89. Z. Guo, S. Raeissi, R.B. White, J.C. Stevens, Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab. Dispos. 25 (1997) 390-393.
90. S. Ohmori, C. Shirakawa, K. Motohashi, H. Yoshida, H. Abe, T. Nakamura, T. Horie, H. Kitigawa, K. Asaoka, T. Rikihisa, Y. Kanakubo, M. Kitada, Purification from liver microsomes from untreated cynomolgous monkeys of cytochrome P450 closely related to human cytochrome P450 2B6, Mol. Pharmacol. 43 (1993) 183-190.
91. C. Ged, D.R. Umbenhauer, T.M. Bellew, R.W. Bork, P.K. Srivastava, N. Shinriki, R.S. Lloyd, F.P. Guengerich, Characterization of cDNAs, mRNAs and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase, Biochemistry 27 (1988) 6929-6940.
92. F.P. Guengerich, A. Parikh, E.F. Johnson, T.H. Richardson, C. von Wachenfeldt, J. Cosme, F. Jung, C.P. Strassburg, M.P. Manns, R.H. Tukey, M. Pritchard, S. Fournel-Gigleux, B. Burchell, Heterolgous expression of human drug-metabolizing enzymes, Drug Metab. Dispos. (1997) (in press).
93. A.E. Rettie, K.R. Korzekwa, K.L. Kunze, R.F. Lawrence, A.C. Eddy, T. Aoyama, H.V. Gelbonin, F.J. Gonzalez, W.F. Trager, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions, Chem. Res. Toxicol. 5 (1992) 54-59.
94. J.A. Goldstein, M.B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J.L. Raucy, J.M. Lasker, B.I. Ghanayem, Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans, Biochemistry 33 (1994) 1743-1752.
95. M.A. Leo, J.M. Lasker, J.L. Raucy, C.I. Kim, M. Black, C.S. Lieber, Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8, Arch. Biochem. Biophys. 269 (1989) 305-312.
96. A. Rahman, K.R. Korzekwa, J. Grogan, F.J. Gonzalez, J.W. Harris, Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8, Cancer Res. 54 (1994) 5543-5546.
97. G.C. Ibeanu, B.I. Ghanayem, P. Linko, L. Li, L.G. Pedersen, J.A. Goldstein, Identification of residues 99, 220 and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity, J. Biol. Chem. 271 (1996) 12496-12501.
98. A.E. Rettie, L.C. Wienkers, F.J. Gonzalez, W.F. Trager, K.R. Korzekwa, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9, Pharmacogenetics 4 (1994) 39-42.
99. L.S. Kaminsky, S.M.F. de Morais, M.B. Faletto, D.A. Dunbar, J.A. Goldstein, Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe, Mol. Pharmacol. 43 (1993) 234-239.
100. L.S. Kaminsky, Z.Y. Zhang, Human P450 metabolism of warfarin, Pharmacol. Today 73 (1997) 67-74.
101. E.F. Johnson, T. Kronbach, M.-H. Hsu, Analysis of the catalytic specificity of cytochrome P-450 enzymes through site-directed mutagenesis, FASEB J. 6 (1992) 700-705.
102. D.J. Waxman, C. Attisano, F.P. Guengerich, D.P. Lapenson, Cytochrome P-450 steroid hormone metabolism catalyzed by human liver microsomes, Arch. Biochem. Biophys. 263 (1988) 424-436.
103. H.H. Dieter, U. Muller-Eberhard, E.F. Johnson, Identification of rabbit microsomal cytochrome P-450 isozyme, form 1, as a hepatic progesterone 21-hydroxylase, Biochem. Biophys. Res. Commun. 105 (1982) 515-520.
104. W.L. Miller, Y. Morel, The molecular genetics of 21-hydroxylase deficiency, Ann. Rev. Genet. 23 (1989) 371-393.
105. T. Kronbach, B. Kemper, E.F. Johnson, A hypervariable region of P450IIC5 confers progesterone 21-hydroxylase activity to P450IIC1, Biochemistry 30 (1991) 6097-6102.
106. M.H. Hsu, K.J. Griffin, Y. Wang, B. Kemper, E.F. Johnson, A single amino acid substitution confers progesterone 6β-hydroxylase activity to rabbit cytochrome P450 2C3, J. Biol Chem. 268 (1993) 6939-6944.
107. T. Uno, Y. Imai, Further studies on chrimeric P450 2C2/2C14 having testosterone 16β-hydroxylase activity which is absent in the parental P450s, J. Biochem. 112 (1992) 155-162.
108. D.J. Waxman, G.A. Dannan, F.P. Guengerich, Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting and xenobiotic inducibility of sex-specific isoenzymes, Biochemistry 24 (1985) 4409-4417.
109. C. Liddle, A. Mode, D. Legraverend, J.Å. Gustafsson, Constitutive expression and hormonal regulation of male sexually differentiated cytochrome P450 in primary cultured rat hepatocytes, Arch. Biochem. Biophys. 298 (1992) 159-166.
110. A. Mahgoub, J.R. Idle, L.G. Dring, R. Lancaster, R.L. Smith, Polymorphic hydroxylation of debrisoquine in man, Lancet ii (1977) 584-586.
111. M. Eichelbaum, N. Spannbrucker, B. Steincke, H.J. Dengler, Defective N-oxidation of sparteine in man: a new pharmacogenetic defect, Eur. J. Clin. Pharmacol. 16 (1979) 183-187.
112. F.J. Gonzalez, R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, D.W. Nebert, H.V. Gelboin, J.P. Hardwick, U.A. Meyer, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature 331 (1988) 442-446.
113. S. Kimura, M. Umeno, R.C. Skoda, U.A. Meyer, F.J. Gonzalez, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene, Am. J. Hum. Genet. 45 (1989) 889-904.
114. E. Matsunaga, U.M. Zanger, J.P. Hardwick, H.V. Gelboin, U.A. Meyer, F.J. Gonzalez, The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats, Biochemistry 28 (1989) 7349-7355.
115. E. Matsunaga, M. Umeno, F.J. Gonzalez, The rat: P450 IID subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme-binding region of the cytochrome P450 active site, J. Mol. Evol. 30 (1990) 155-169.
116. K. Sakamoto, S. Kirita, T. Baba, Y. Nakamura, Y. Yamazoe, R. Kato, A. Takanaka, T. Matsubara, A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning and enzyme characterization, Arch. Biochem. Biophys. 319 (1995) 372-382.
117. E. Jacqz-Aigrain, M. Gueguen, U.M. Zanger, I. Robieux, F. Alvarez, Cytochrome P450IID subfamily in non-human primates: catalytical and immunological characterization, Biochem. Pharmacol. 41 (1991) 1657-1663.
118. S.V. Otton, R.F. Tyndale, D. Wu, T. Inaba, W. Kalow, E.M. Sellers, Catalytic and immunologic similarities between monkey and human liver cytochrome P-450dbl (human cytochrome P-450 2D6), Drug Metab. Dispos. 20 (1992) 1-5.
119. G. Strobl, B. Heinrich, T. Wolff, F.P. Guengerich, Inhibition of bufuralol 1′-hydroxylation in rat and human liver: in vitro studies and inhibitor modeling. In: Abstracts. Sixth Symposium on Biochemistry and Biophysics of Cytochrome P-450, July, Vienna, 1988.
120. G.R. Strobl, S. von Kruedener, J. Stöckigt, F.P. Guengerich, T. Wolff, Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies, J. Med. Chem. 36 (1993) 1136-1145.
121. S.W. Ellis, G.P. Hayhurst, G. Smith, T. Lightfoot, M.M.S. Wong, A.P. Simula, M.J. Ackland, M.J.E. Sternberg, M.S. Lennard, G.T. Tucker, C.R. Wolf, Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6, J. Biol. Chem. 270 (1995) 29055-29058.
122. max of the enzyme for bufuralol but not debrisoquine hydroxylation, J. Biol. Chem. 265 (1990) 17197-17201.
123. S.W. Ellis, K. Rowland, M.J. Ackland, E. Rekka, A.P. Simula, M.S. Lennard, C.R. Wolf, G.T. Tucker. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio-and enantio-selective metabolism of metroprolol, Biochem. J. 316 (1996) 647-654.
124. D.E. Ryan, L. Ramanathan, S. Iida, P.E. Thomas, M. Haniu, J.E. Shively, C.S. Lieber, W. Levin, Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid, J. Biol Chem. 260 (1985) 6385-6393.
125. 5, Arch. Biochem. Biophys. 251 (1986) 629-638.
126. D.R. Koop, E.T. Morgan, G.E. Tarr, M.J. Coon, Purification and characterization of a unique isozyme of cytochrome P-450 from liver microsomes of ethanol-treated rabbits, J. Biol. Chem. 257 (1982) 8472-8480.
127. S.A. Wrighton, P.E. Thomas, D.E. Ryan, W. Levin, Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj, Arch. Biochem. Biophys. 258 (1987) 292-297.
128. F.P. Guengerich, D.-H. Kim, M. Iwasaki, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects, Chem. Res. Toxicol. 4 (1991) 168-179.
129. F.J. Gonzalez, The molecular biology of cytochrome P450s, Pharmacol. Rev. 40 (1989) 243-288.
130. C.S. Yang, J.S.H. Yoo, H. Ishizaki, J. Hong, Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation, Drug Metab. Rev. 22 (1990) 147-159.
131. T. Fukuda, Y. Imai, M. Komori, M. Nakamura, E. Kusunose, K. Satouchi, M. Kusunose, Replacement of Thr-303 of P450 2E1 with serine modifies the regioselectivity of its fatty acid hydroxylase activity, J. Biochem. 113 (1993) 7-12.
132. Y. Tan, S.P. White, S.R. Parawithana, C.S. Yang, A hypothetical model for the active site of human cytochrome P4502E1, Xenobiotica 27 (1997) 287-299.
133. S.E. Clarke, S.J. Baldwin, J.C. Bloomer, A.D. Ayrton, R.S. Sozio, R.J. Chenery, Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes, Chem. Res. Toxicol. 7 (1994) 836-842.
134. Y. Amet, F. Berthou, S. Baird, Y. Dreano, J.P. Bail, J.F. Menez, Validation of the (ω-1)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1, Biochem. Pharmacol. 50 (1995) 1775-1782.
135. F.P. Guengerich, L.C. Bell, O. Okazaki, Interpretations of cytochrome P450 mechanisms from kinetic studies, Biochimie 77 (1995) 573-580.
136. X. Ding, S.J. Pernecky, M.J. Coon, Purification and characterization of cytochrome P450 2E2 from hepatic microsomes of neonatal rabbits, Arch. Biochem. Biophys. 291 (1991) 270-276.
137. M. Komori, K. Nishio, M. Kitada, K. Shiramatsu, K. Muroya, M. Soma, K. Nagashima, T. Kamataki, Fetus-specific expression of a form of cytochrome P-450 in human livers, Biochemistry 29 (1990) 4430-4433.
138. J.D. Schuetz, S. Kauma, P.S. Guzelian, Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta, J. Clin. Invest. 92 (1993) 1018-1024.
139. K. Nagata, F.J. Gonzalez, Y. Yamazoe, R. Kato, Purification and characterization of four catalytically active testosterone 6β-hydroxylase P-450s from rat liver microsomes: comparison of a novel form with three structurally and functionally related forms, J. Biochem. 107 (1990) 718-725.
140. A. Mahnke, D. Stronkamp, P.H. Roos, W.G. Hanstein, G.G. Chabot, P. Nef, Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver, Arch. Biochem. Biophys. 337 (1997) 62-68.
141. S. Imaoka, Y. Imai, T. Shimada, Y. Funae, Role of phospholipids in reconstituted cytochrome P450 3A forms and mechanism of their activation of catalytic activity, Biochemistry 31 (1992) 6063-6069.
142. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 325 (1996) 174-182.
143. T. Aoyama, S. Yamano, D.J. Waxman, D.P. Lapenson, U.A. Meyer, V. Fischer, T. Tyndale, T. Inaba, W. Kalow, H.V. Gelboin, F.J. Gonzalez, Cytochrome P450 hPCN3, a novel cytochrome P-450 IIA gene product that is differentially expressed in adult human liver, J. Biol. Chem. 264 (1989) 10388-10395.
144. 1 by bacterial recombinant human cytochrome P450 enzymes, Chem. Res. Toxicol. 8 (1995) 218-225.
145. M. Kitada, T. Kamataki, K. Itahashi, T. Rikihisa, R. Kato, Y. Kanakubo, Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch. Biochem. Biophys. 241 (1985) 275-280.
146. T. Kamataki, H. Hashimoto, M. Shimoji, S. Itoh, K. Nakayama, K. Hattori, T. Yokoi, M. Katsuki, S. Aizawa, Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice, Toxicol. Lett. 82/83 (1995) 879-882.
147. H. Hashimoto, Y. Yanagawa, M. Sawada, S. Itoh, T. Deguchi, T. Kamataki, Simultaneous expression of human CYP3A7 and N-acetyltransferase in Chinese hamster CHL cells results in high cytotoxicity for carcinogenic heterocyclic amines, Arch. Biochem. Biophys. 320 (1995) 323-329.
148. E.M.J. Gillam, R.M. Wunsch, Y.-F. Ueng, T. Shimada, P.E.B. Reilly, T. Kamataki, F.P. Guengerich, Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5′ modification and catalytic characterization of recombinant enzymes expressed in bicistronic format with NADPH-cytochrome P450 reductase, Arch. Biochem. Biophys. (1997) (in press).
149. M. Kitada, T. Kamataki, K. Itahashi, T. Rikihisa, Y. Kanakubo, Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations, Biochem. Pharmacol. 36 (1987) 453-456.
150. 5, NADPH-P450 reductase and lipid on the rate fo 6β-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein, Arch. Biochem. Biophys. 318 (1995) 314-321.
151. H. Yamazaki, Y.-F. Ueng, T. Shimada, F.P. Guengerich, Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of iron-sulfur proteins and oxygen surrogates, Biochemistry 34 (1995) 8380-8389.
152. 5, J. Biol. Chem. 271 (1996) 27438-27444.
153. J.A.R. Blake, M. Pritchard, S. Ding, G.C.M. Smith, B. Burchell, C.R. Wolf, T. Friedberg, Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli, FEBS Lett. 397 (1996) 210-214.
154. 55, Arch. Biochem. Biophys. (1997) (in press).
155. Y.-F. Ueng, T. Kuwabara, Y.-J. Chun, F.P. Guengerich, Cooperativity in oxidations catalyzed by cytochrome P450 3A4, Biochemistry 36 (1997) 370-381.
156. G.R. Harlow, J.R. Halpert, Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4: role of residues 210 and 211 in flavanoid activation and substrate specificity, J. Biol. Chem. 272 (1997) 5396-5402.
157. Y.A. He, Y.Q. He, G.D. Szklarz, J.R. Halpert, Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis, Biochemistry 36 (1997) 8831-8839.
158. 5 in the biosynthesis of androgens by human P450c17, Arch. Biochem. Biophys. 317 (1995) 343-347.
159. 17α, Mol. Endocrinol. 5 (1991) 1373-1380.
160. 17α chimeric proteins: evidence for distinct tertiary structures in the same P450 from two different species, Biochemistry 29 (1990) 9819-9824.
161. C.W. Fisher, D.L. Candle, C. Martin-Wixtrom, L.C. Quattrochi, R.H. Tukey, M.R. Waterman, R.W. Estabrook, High-level expression of functional cytochrome P450 1A2 in Escherichia coli, FASEB J. 6 (1992) 759-764.
162. F.P. Guengerich, M.V. Martin, P.H. Beaune, P. Kremers, T. Wolff, D.J. Waxman, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism, J. Biol. Chem. 261 (1986) 5051-5060.
163. T. Shimada, F.P. Guengerich, Participation of a rat liver cytochrome P-450 induced by pregnelone 16α-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin, Mol. Pharmacol. 28 (1985) 215-219.
164. T. Shimada, K.S. Misono, F.P. Guengerich, Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction, J. Biol. Chem. 261 (1986) 909-921.
165. RAP), Endocrinology 131 (1995) 3067-3076.
166. C.L. Hayes, D.C. Spink, B.C. Spink, J.Q. Cao, N.J. Walker, T.R. Sutter, 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1, Proc. Natl. Acad. Sci. USA 93 (1996) 9776-9781.
167. T. Shimada, C.L. Hayes, H. Yamazaki, S. Amin, S.S. Hecht, F.P. Guengerich, T.R. Sutter, Activation of chemically diverse procarcinogens by human cytochrome P450 1B1, Cance Res. 56 (1996) 2979-2984.
168. M. Nishimoto, J.E. Clark, B.S.S. Masters, Cytochrome P450 4A4: expression in Escherichia coli, purification and characterization of catalytic properties, Biochemistry 32 (1993) 8863-8870.
169. L.J. Roman, C.N.A. Palmer, J.E. Clark, A.S. Muerhoff, K.J. Griffin, E.F. Johnson, B.S.S. Masters. Expression of rabbit cytochromes P4504A which catalyze the ω-hydroxylation of arachidonic acid, fatty acids and prostaglandins, Arch. Biochem. Biophys. 307 (1993) 57-65.
170. C.S. Chaurasia, M.A. Alterman, P. Lu, R.P. Hanzlik, Biochemical characterization of lauric acid ω-hydroxylation by a CYP4A1/NADPH-cytochrome P450 reductase fusion protein. Arch. Biochem. Biophys. 317 (1995) 161-169.